Advances in thyroglobulin assays and their impact on the management of differentiated thyroid cancers

2016 ◽  
Vol 74 (1) ◽  
pp. 21-27
Author(s):  
Michèle d’Herbomez ◽  
Georges Lion ◽  
Amandine Béron ◽  
Jean-Louis Wémeau ◽  
Christine DoCao
Keyword(s):  
Thyroid Cancers ◽  
Differentiated Thyroid Cancers

Abstract #60: PTEN Promoter Methylation is Specifically Detected in Differentiated Thyroid Cancers

2003 ◽  
Vol 9 ◽  
pp. 23-24
Author(s):  
Francisco Alvarez ◽  
Helena Bussaglia ◽  
Monica Vilar ◽  
Juan Ybarra ◽  
Alberto de Leiva ◽  
...  
Keyword(s):  
Promoter Methylation ◽  
Thyroid Cancers ◽  
Differentiated Thyroid Cancers

scholarly journals Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular Identities

2021 ◽  
Vol 22 (6) ◽  
pp. 3117
Author(s):  
Loredana Lorusso ◽  
Virginia Cappagli ◽  
Laura Valerio ◽  
Carlotta Giani ◽  
David Viola ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Kinase Inhibitors ◽  
Therapeutic Option ◽  
Progression Free Survival ◽  
Thyroid Cancers ◽  
Poorly Differentiated ◽  
Differentiated Thyroid Cancers ◽  
Approved Drugs ◽  
New Generation ◽  
Systemic Therapies

Differentiated thyroid cancers (DTC) are commonly and successfully treated with total thyroidectomy plus/minus radioiodine therapy (RAI). Medullary thyroid cancer (MTC) is only treated with surgery but only intrathyroidal tumors are cured. The worst prognosis is for anaplastic (ATC) and poorly differentiated thyroid cancer (PDTC). Whenever a local or metastatic advanced disease is present, other treatments are required, varying from local to systemic therapies. In the last decade, the efficacy of the targeted therapies and, in particular, tyrosine kinase inhibitors (TKIs) has been demonstrated. They can prolong the disease progression-free survival and represent the most important therapeutic option for the treatment of advanced and progressive thyroid cancer. Currently, lenvatinib and sorafenib are the approved drugs for the treatment of RAI-refractory DTC and PDTC while advanced MTC can be treated with either cabozantinib or vandetanib. Dabrafenib plus trametinib is the only approved treatment by FDA for BRAFV600E mutated ATC. A new generation of TKIs, specifically for single altered oncogenes, is under evaluation in phase 2 and 3 clinical trials. The aim of this review was to provide an overview of the current and future treatments of thyroid cancer with regards to the advanced and progressive cases that require systemic therapies that are becoming more and more targeted on the molecular identity of the tumor.

scholarly journals Thyroid functional parameters and correlative autoantibodies as prognostic factors for differentiated thyroid cancers

Oncotarget ◽  
2016 ◽  
Vol 7 (31) ◽  
pp. 49930-49938 ◽  
Author(s):  
Chao Li ◽  
Wenbin Yu ◽  
Jinchuan Fan ◽  
Guojun Li ◽  
Xiaofeng Tao ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Thyroid Cancers ◽  
Functional Parameters ◽  
Differentiated Thyroid Cancers

scholarly journals Extent of Thyroidectomy in Differentiated Thyroid Cancers—Review of Evidence

2017 ◽  
Vol 9 (1) ◽  
pp. 90-96 ◽  
Author(s):  
Samskruthi P. Murthy ◽  
Deepak Balasubramanian ◽  
Adharsh Anand ◽  
Shashikant Vishnubhai Limbachiya ◽  
Narayana Subramaniam ◽  
...  
Keyword(s):  
Thyroid Cancers ◽  
Differentiated Thyroid Cancers

Abstract 3361: Methylome differences in differentiated thyroid cancers and benign adenomas

2017 ◽  
Author(s):  
Josena K. Stephen ◽  
Kang Mei Chen ◽  
Jason Merritt ◽  
Indrani Datta ◽  
Dhananjay Chitale ◽  
...  
Keyword(s):  
Thyroid Cancers ◽  
Differentiated Thyroid Cancers
Sign in / Sign up

Export Citation Format

Share Document